Adjuvant radiotherapy was administered less often in HR+/HER2− IBC (60.9%), compared to HER2-enriched (66.7%), HR−/HER2− (66.3%), and HR+/HER2+ (65.9%) IBC (Table 2). This evidence concerns the gene HR and inflammatory breast carcinoma.